Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
3 patents granted to the 3 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Cogent Biosciences, Inc.’s names, not what it holds today.
Patents granted
3
3 utility, 1976 to Dec 31, 2025
Granted in 2025
2
in the last year the record reads
Applications published
13
4 of them in 2025
Names they are printed under
3
a former name, its own name
By yearGrantedApplications published
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Organic fine chemistry1
Pharmaceuticals1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name3 counted
Unum Therapeutics Inc. a former name
US, as the owner printed on each patent
7 publishedCogent Biosciences, Inc. its own name
named as the applicant on its applications, in US
6 publishedCogent Biosciences, Inc. its own name
US, as the owner printed on each patent
0 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Jul 8, 2025 | 12,351,581 | Compounds for FGFR inhibition | Pharmaceuticals | Cogent Biosciences, Inc. |
| Apr 22, 2025 | 12,281,122 | PI3K inhibitors | Organic fine chemistry | Cogent Biosciences, Inc. |
| Dec 4, 2018 | 10,144,770 | Chimeric receptors and uses thereof in immune therapy | Biotechnology | Unum Therapeutics Inc. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Aug 28, 2025 | 2025/0270211 | COMPOUNDS FOR FGFR INHIBITION | Pharmaceuticals | Cogent Biosciences, Inc. |
| Jun 26, 2025 | 2025/0206752 | PI3K INHIBITORS | Organic fine chemistry | Cogent Biosciences, Inc. |
| Apr 24, 2025 | 2025/0129078 | ERBB2 INHIBITORS | Organic fine chemistry | Cogent Biosciences, Inc. |
| Feb 27, 2025 | 2025/0066352 | COMPOUNDS FOR FGFR INHIBITION | Pharmaceuticals | Cogent Biosciences, Inc. · patent 12,351,581 granted from it |
| Aug 15, 2024 | 2024/0270741 | COMPOUNDS FOR FGFRS INHIBITORS | Pharmaceuticals | Cogent Biosciences, Inc. |
| Jul 4, 2024 | 2024/0216347 | BEZUCLASTINIB FORMULATIONS | Pharmaceuticals | Cogent Biosciences, Inc. |
| Jun 11, 2020 | 2020/0181226 | ANTIBODY-COUPLED T CELL RECEPTOR CONSTRUCTS AND THERAPEUTIC USES THEREOF | Biotechnology | Unum Therapeutics Inc. |
| Dec 19, 2019 | 2019/0381171 | CO-USE OF ANTI-BCMA ANTIBODY AND ANTIBODY-COUPLED T CELL RECEPTOR (ACTR) IN CANCER THERAPY AND B CELL DISORDERS | Pharmaceuticals | Unum Therapeutics Inc. |
| Sep 19, 2019 | 2019/0284298 | USE OF ANTIBODY-COUPLED T CELL RECEPTOR (ACTR) WITH MULTIPLE ANTI-CANCER ANTIBODIES IN CANCER TREATMENT | Biotechnology | Unum Therapeutics Inc. |
| Apr 18, 2019 | 2019/0112349 | MODIFIED CHIMERIC RECEPTORS AND USES THEREOF IN IMMUNE THERAPY | Medical technology | Unum Therapeutics Inc. |
What it applied for, 2024 to 2025: Pharmaceuticals 4 · Organic fine chemistry 2.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.